Status:
COMPLETED
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Breast Cancer
Arthralgia
Eligibility:
FEMALE
18+ years
Brief Summary
Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the ...
Eligibility Criteria
Inclusion
- Stage 0-III breast cancer who are scheduled to receive endocrine therapy with tamoxifen or an aromatase inhibitor
- All prior surgery and chemotherapy should be complete
- Age 18 and above and postmenopausal
Exclusion
- Major rheumatologic disorders
- Concomitant sex hormone containing drugs or Leutinizing Hormone Releasing Hormone agonist therapy
- For those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen within 4 weeks of enrollment
- For those subjects initiating treatment with tamoxifen, prior aromatase inhibitor within 4 weeks of enrollment
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT01896050
Start Date
September 1 2009
End Date
August 1 2014
Last Update
June 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109